Ningbo Eye Hospital
Ningbo, Zhejiang, 315040, China
Completed
NCT Number: NCT06567028
OSPM-Enhanced AI Model to Identify Premalignant and Malignant Ocular Surface Tumors
An OSPM-enhanced deep learning model has been developed for identifying premalignant and malignant tumors using data retrospectively collected from the Ningbo Eye Hospital, Jiangdong Eye Hospital, and the Eye Hospital of Wenzhou Medical University. To further substantiate the model's effectiveness, we intend to evaluate it prospectively at Ningbo Eye Hospital.
Completed
Looking for future studies?
Notify MeKey information
Conditions
Age range
1 year–100 year
Sex eligibility
All sexes
Study type
Observational
Primary location
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
● Ocular surface tumor images with histopathological findings
Exclusion criteria
● Low-quality images
Treatment and study plan
OSPM-Enhanced AI Model
Diagnostic TestAnalyze tumor images using the model developed in our study
Primary outcomes
-
AUROC
Time frame: 3 months
area under the receiver operating characteristic curve
Sponsors and collaborators
Lead sponsor
Ningbo Eye Hospital
Other
Registry information
Official study title
Prospective Evaluation of an OSPM-Enhanced Deep Learning Model for Identifying Premalignant and Malignant Ocular Surface Tumors
Important dates
- Study start
- 2024
- Primary completion
- 2024
- Study completion
- 2024
- First posted
- Aug 22, 2024
- Registry last updated
- Mar 26, 2025
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.